Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (14)

« Back to Publications

Kidney function and mortality in Mexico: prospective study of 130 000 adults

Aguilar Ramirez D. et al, (2026), Kidney Medicine

Effects of Empagliflozin on Kidney and Cardiac Magnetic Resonance Imaging Measures in Patients With CKD: An EMPA-KIDNEY Mechanistic Substudy.

Zhu D. et al, (2025), Am J Kidney Dis

Blood Pressure and Mortality in Mexico City: A Mendelian Randomization Study.

Turner M. et al, (2025), Hypertension, 82, 1896 - 1905

The prevention and management of chronic kidney disease among patients with metabolic syndrome.

Zhu D. et al, (2025), Kidney Int, 107, 816 - 824

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.

Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

EMPA-KIDNEY Collaborative Group . et al, (2025), N Engl J Med, 392, 777 - 787

Design considerations for future renoprotection trials in the era of multiple therapies for chronic kidney disease.

Zhu D. et al, (2025), Nephrol Dial Transplant, 40, i70 - i79

In adults with BMI ≥27 kg/m2 and CVD, but without diabetes, semaglutide reduced MACE, regardless of baseline HbA1c level.

Zhu D. and Herrington WG., (2024), Ann Intern Med, 177

In HF, T2D, CKD, or atherosclerotic CVD, SGLT2 inhibitors reduce HF hospitalizations and CV mortality.

Zhu D. and Herrington WG., (2024), Ann Intern Med, 177

Blood Pressure, eGFR, and Kidney Mortality in Mexico: A Prospective Study of 150,000 Adults

Zhu D., (2024)

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.

Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129

Improvements in Kidney Outcomes Over the Years: Reason for Optimism but a Challenge for Trialists.

Zhu D. et al, (2024), Am J Kidney Dis, 83, 427 - 428

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

EMPA-KIDNEY Collaborative Group ., (2024), Lancet Diabetes Endocrinol, 12, 51 - 60

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.

EMPA-KIDNEY Collaborative Group ., (2024), Lancet Diabetes Endocrinol, 12, 39 - 50